Hardeep Singh
Satish Mehta, a second-generation business genius, founded Emcure Pharmaceuticals long before the phrases “Made in India” or “Work in India” were popular.
Established in 1981 as a contract manufacturer for global pharma behemoths, the Pune-based corporation went on to build and market its own brand generic foundations in 70 countries, becoming one of the leading companies in the field.
Emcure has built an organisation of 19 subsidiaries, an R&D team of 500 researchers, and a global labour force of 11,000 people in recent years. Its lifetime earnings are approaching Rs 6,000 crore, with only 44 percent originating from the domestic market.
According to CRISIL, the business enrolled in a YoY topline development of 15% in the first half of 2021 and is now planning for a Rs 4,000 crore IPO.
Satish returned to Pune with a PG diploma from IIM-A and began working in his father’s firm to become acquainted with the pharma exchange’s tricks. In the mid-1980s, driven by the urge to create something on his own, he took out a bank loan and dispatched Emcure.
It took a lot of guts to turn a Rs 3 lakh investment into a billion-dollar enterprise. Add to that Satish’s growing riches. On the Forbes Rich List in 2016, he was ranked as the 82nd most wealthy Indian, with a total net worth of $1.6 billion.
Namita Thapar (Investor at Shark Tank India)
Namita Thapar here involves everything about the Executive Director of Emcure Pharmaceutical who is an Investor at Shark Tank India. Namita Thapar, one of India’s leading businesswomen, is the CEO of Emcure Pharmaceuticals, an Indian multinational pharmaceutical company based in Pune, Maharashtra. While she is a familiar face in the business world, she has come into the public eye as an investor in Shark Tank India.
A globally diverse pharmaceutical enterprise
Emcure now offers a broader income profile, with more than 56 percent of agreements originating from international business sectors. This includes 13% from growing business sectors, 31% from regulated markets (the United States and Canada), and 12% from Europe.
In the domestic market, the Bain Capital-backed organisation values administrative responsibilities in major therapeutic segments such as cardiology, oncology, anti-HIV, and neurology. It also has a working presence in anti-infective disease, pain management, dermatology, gynecology, and pediatrics. Emcure products such as Maxtra, Metpure, Asomex, Orofer, Bevon, and Ferium have a strong presence in the Indian pharmaceutical industry.
According to the forefather, “When I started my career, medicines were only available in major cities like Mumbai. Our organisation now has 4,600 clinical delegates. As a result, modern medicine is reaching urban areas, semi-metropolitan areas, and even rural areas.”
Decision-making and consensus-building
Pharma is a highly competitive and divisive industry. Add to that, a Pune-based firm in the 1980s had its own set of challenges. As a result, Emcure’s primary crucial decision was to improve its backend, such as generating.
During the 1990s, when indigenous organisations like Cipla, Sun Pharma, Cadila, and others came to dominate India’s pharma landscape, Emcure began to deliver and market its own goods.
It was difficult, though, with Satish’s own friends warning him of impending dangers.
Emcure expanded into growing business sectors in Africa, Asia, and Latin America in the late 1990s and early 2000s. When it was completed, it began concentrating on the controlled markets of North America and Europe. Calibration was the key to its approach.
Satish has hired people “more smarter” than him along the way, and he has also included his children in the firm. It has resulted in a mix of initiative styles at Emcure, as well as a perfect balance between the MD’s inherited frameworks and the fashionable outstanding talent of his friends and family.
Future of Emcure – mRNA vaccines
Despite being in the inheritance industry, Emcure is optimistic about scientific progress.
The next big bet is on mRNA antibodies for COVID-19. “We’re dealing with it, and it’ll be just like the Pfizer and Moderna vaccines,” Satish asserts.
According to media sources, the pharmaceutical company is presently submitting material to the Central Drugs Standard Control Organisation (CDSCO) and asking for funds for the next stage preliminaries.
Despite increased attention to medical care, India’s per capita pharmaceutical use remains extremely low. In any event, according to the most recent Union Budget, consumption in the area is poised to rise from 1.6 percent to 2.5 percent of GDP.
Satish explains: “The domestic market is worth around $20 billion [Emcure has a 2.8 percent stake] and is expected to expand to $35 billion every seven to eight years. Even if we just have a 3.2 percent market share in India, we may aim to become a billion-dollar company. This allows you to visualise [the development potential].”
